Qingdao Haier Biomedical Co.,Ltd

Equities

688139

CNE100003P25

Advanced Medical Equipment & Technology

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
36.93 CNY +7.17% Intraday chart for Qingdao Haier Biomedical Co.,Ltd +12.59% -8.86%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Qingdao Haier Biomedical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Qingdao Haier Biomedical Co.,Ltd's Equity Buyback Plan announced on February 9, 2024. CI
Qingdao Haier Biomedical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Qingdao Haier Biomedical Co.,Ltd announces an Equity Buyback for CNY 50 million worth of its shares. CI
Qingdao Haier Biomedical Co.,Ltd authorizes a Buyback Plan. CI
CICC Elects Chairman, Vice Chairman MT
Jefferies Adjusts Qingdao Haier Biomedical’s Price Target to 80 Yuan From 100 Yuan, Keeps at Buy MT
Qingdao Haier Biomedical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Jefferies Adjusts Qingdao Haier Biomedical's Price Target to 100 Yuan From 120 Yuan, Keeps at Buy MT
Qingdao Haier Biomedical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shanghai Chaoli'an Technology Co., Ltd. announced that it expects to receive CNY 43 million in funding from Qingdao Haier Biomedical Co.,Ltd CI
Qingdao Haier Biomedical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Jefferies Adjusts Qingdao Haier Biomedical’s Price Target to 120 Yuan From 126 Yuan, Keeps at Buy MT
Qingdao Haier Biomedical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tranche Update on Qingdao Haier Biomedical Co., Ltd's Equity Buyback Plan announced on February 7, 2022. CI
Qingdao Haier Biomedical Co., Ltd's Equity Buyback announced on February 7, 2022, has expired with 1,459,586 shares, representing 0.46% for CNY 99.69 million. CI
Tranche Update on Qingdao Haier Biomedical Co., Ltd's Equity Buyback Plan announced on February 7, 2022. CI
Beijing residents break free from COVID lockdown RE
Qingdao Haier Biomedical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Qingdao Haier Biomedical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Suzhou Basecare Signs Strategic Collaboration Framework Deal with Qingdao Haier Biomedical MT
Tranche Update on Qingdao Haier Biomedical Co., Ltd's Equity Buyback Plan announced on February 7, 2022. CI
Qingdao Haier Biomedical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Tranche Update on Qingdao Haier Biomedical Co., Ltd's Equity Buyback Plan announced on February 7, 2022. CI
Qingdao Haier Biomedical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Chart Qingdao Haier Biomedical Co.,Ltd
More charts
Qingdao Haier Biomedical Co Ltd is a China-based company mainly engaged in the research and development (R&D), production and sales of biomedical low-temperature storage products. The Company's main businesses include: providing biomedical low-temperature storage solutions covering the whole temperature range for scenarios such as sample safety, drug and reagent safety, vaccine safety and blood safety, as well as automatic, intelligent and comprehensive upgrading based on user needs, and providing integrated solutions for Internet of Thing (IoT) scenarios covering a variety of biosafety products. The Company's products are sold to domestic and overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
36.93 CNY
Average target price
57.5 CNY
Spread / Average Target
+55.70%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688139 Stock
  4. News Qingdao Haier Biomedical Co.,Ltd
  5. Jefferies Adjusts Qingdao Haier Biomedical's Price Target to 100 Yuan From 120 Yuan, Keeps at Buy